Fractional exhaled nitric oxide in childhood is associated with 17q11.2-q12 and 17q12-q21 variants

A full list of authors and affiliations appears at the end of the article.
# These authors contributed equally to this work.

Abstract

**Background**—The fractional concentration of nitric oxide in exhaled air (FeNO) is a biomarker of eosinophilic airway inflammation and associated with childhood asthma. Identification of common genetic variants associated with childhood FeNO may help to define biological mechanisms related to specific asthma phenotypes.

**Objective**—To identify genetic variants associated with childhood FeNO, and their relation with asthma.

**Methods**—FeNO was measured in children aged 5 to 15 years. In 14 genome-wide association (GWA) studies (N = 8,858), we examined the associations of ~2.5 million single nucleotide polymorphisms (SNPs) with FeNO. Subsequently, we assessed whether significant SNPs were expression quantitative trait loci (eQTLs) in genome-wide expression datasets of lymphoblastoid cell lines (N = 1,830), and were related with asthma in a previously published GWA dataset (cases: n=10,365; controls: n=16,110).

**Results**—We identified 3 SNPs associated with FeNO: rs3751972 in *LYR motif containing 9* (*LYRM9*) (*P* = 1.97×10^{-10}) and rs944722 in *inducible nitric oxide synthase 2* (*NOS2*) (*P* = 1.28×10^{-9}) both located at 17q11.2-q12, and rs8069176 near *gasdermin B* (*GSDMB*) (*P* = 1.88×10^{-8}) at 17q12-q21. We found a *cis* eQTL for the transcript *soluble galactoside-binding lectin 9* (*LGALS9*) that is in linkage disequilibrium with rs944722. Rs8069176 was associated with *GSDMB* and *ORM1-like 3* (*ORMDL3*) expression. Rs8069176 at 17q12-q21, and not rs3751972 and rs944722 at 17q11.2-q12, were associated with physician-diagnosed asthma.

**Conclusion**—This study identified 3 variants associated with FeNO, explaining 0.95% of the variance. Identification of functional SNPs and haplotypes in these regions might provide novel insight in the regulation of FeNO. This study highlights that both shared and distinct genetic factors affect FeNO and childhood asthma.
Keywords
airway inflammation; asthma phenotypes; biomarker; genetics; genome-wide association study

INTRODUCTION

Asthma is a complex disease with different phenotypes, influenced by many genetic and environmental factors. Why children develop specific asthma phenotypes is still poorly understood. Genetic association studies may help to identify biological pathways underlying the clinical expression of asthma. Recent genome-wide association (GWA) studies provided evidence that different common genetic variants are associated with specific asthma-related outcomes such as childhood onset asthma, adult asthma, impaired lung function, and atopy.

The fractional concentration of nitric oxide in exhaled air (FeNO) is a noninvasive biomarker of eosinophilic airway inflammation. Higher FeNO is associated with childhood asthma symptoms, exacerbations, physician-diagnosed asthma and atopy. Nitric oxide is a reactive free-radical gas generated in the airway epithelium when L-arginine is oxidized to L-citrulline. This reaction is catalyzed by nitric oxide synthases (NOS), that are upregulated in the presence of pro-inflammatory cytokines and inflammatory mediators. Nitric oxide regulates airway and blood vessel tone and high concentrations have antimicrobial effects. Although 60% of the variance in FeNO in adults can be explained by heritability, the genetic loci that influence FeNO are largely unknown. Identification of common genetic variants associated with childhood FeNO may help to define biological mechanisms related to specific asthma phenotypes.

To identify common genetic variants associated with childhood FeNO, we examined the association of ~2.5 million directly genotyped and imputed single nucleotide polymorphisms (SNPs) with FeNO in 14 independent pediatric discovery GWA studies (N = 8,858).

METHODS

FeNO was measured online in children aged 5 to 15 years according to European Respiratory Society (ERS) and American Thoracic Society (ATS) guidelines. FeNO was natural-log transformed to obtain a normal distribution. We applied linear regression between allele dosages obtained from imputations and natural-log FeNO adjusted for sex and age at time of measurement. Details on the SNP discovery analysis and additional analyses, including the analysis to determine independent SNP effects, explained variance analyses and stratified analysis for current asthma, are presented in the Online Repository Materials methods section, and an overview of our study design is outlined in Figure I. Details on individual study characteristics, SNP genotyping platforms and study association analyses are provided in Repository Table E1.

We assessed whether significant SNPs or SNPs in linkage disequilibrium (LD, a measure of correlation between SNPs) with our lead SNPs were functional annotated SNPs using HaploReg and SIFT (http://sift.jcvi.org/), and were situated in genomic loci that are
involved in the regulation of messenger RNA expression (the so-called ‘expression quantitative trait loci’ or eQTLs). For the second purpose we used available genome-wide expression datasets of human lymphoblastoid cell lines (N = 1,830)\textsuperscript{25, 26}.

We tested the relation of significant SNPs with asthma using a previously published GWA dataset of physician-diagnosed asthma (cases: n=10,365; controls: n=16,110)\textsuperscript{5}. We explored whether the SNPs identified in the present GWA study were related with FeNO in adults in the Epidemiological study on the Genetics and Environment of Asthma (EGEA) and in Hutterites (N = 1,211).

Finally, we explored whether common genetic variants known to be associated with physician-diagnosed asthma\textsuperscript{5} were related with childhood FeNO.

The institutional review boards for human studies approved the protocols and written consent was obtained from the participating subjects or their caregivers if required by the institutional review board.

RESULTS

We identified genome-wide significant ($P < 5 \times 10^{-8}$) association of childhood FeNO and SNPs at 3 genetic loci. Two SNPs were located at chromosome 17q11.2-q12: the SNP rs3751972 in the \textit{LYR motif containing 9 (LYRM9)} gene and rs944722 in the \textit{NOS2} gene (Table I). Each C allele of rs3751972 was associated with higher ln(FeNO) ($\beta = 0.09$ ppb; S.E. = 0.014; $P = 1.97 \times 10^{-10}$; explained variance = 0.23%), and each C allele of rs944722 was associated with lower ln(FeNO) ($\beta = -0.07$ ppb; S.E. = 0.012; $P = 1.28 \times 10^{-9}$; explained variance = 0.30%). Rs3751972 and rs944722 are in neighboring loci with low LD, indicating that the two SNPs might not represent the same genetic variation (HapMap pairwise LD, phase II release 22 CEU; $D' = 0.237$, $r^2 = 0.014$). A third SNP, rs8069176 near the \textit{gasdermin B (GSDMB)} gene at 17q12-q21 was also associated with childhood FeNO. Each A allele of rs8069176 was associated with lower ln(FeNO) ($\beta = -0.07$ ppb; S.E. = 0.012; $P = 1.88 \times 10^{-8}$; explained variance = 0.41%). Figure II-IV show the QQ-, Manhattan-, regional association- and forest plots of the 3 signals.

We used the genome-wide complex trait analysis (GCTA) tool to determine if SNP effects were independent. We conditioned on all SNPs of the meta-analysis\textsuperscript{27}, and showed that rs3751972 and rs944722 were indeed independent signals and did not represent the same genetic variation (Repository Table E2). After conditioning on all SNPs of the meta-analysis, rs3751972 and rs2274894 showed the strongest association in the \textit{LYRM9} gene ($P = 2.06 \times 10^{-9}$) and in the \textit{NOS2} gene ($P = 1.50 \times 10^{-8}$, rs2274894 not rs944722 is the strongest signal using GCTA) respectively. Using the same approach, rs8069176 showed the strongest association at 17q12-q21 ($P = 2.14 \times 10^{-8}$).

The 3 genome-wide significant SNPs showed low heterogeneity between studies (all $P \geq 0.075$, $I^2 = 0 – 37.8\%$). The 3 SNPs together explained 0.95% of the variance in FeNO. Other suggestive loci that were associated with FeNO, but did not reach genome-wide significance ($P < 1 \times 10^{-5}$), are given in Repository Tables E3 and E4. The associations of genetic variants in the \textit{nitric oxide synthases} or \textit{arginase} genes might be different among...
asthmatic versus non-asthmatic children. Therefore, we performed a sensitivity analysis adjusting for current asthma and this produced comparable results for the SNPs in \textit{LYRM9} and \textit{NOS2} and a slightly lower effect for the SNP in the 17q12-q21 locus (Repository Table E5). In addition, we showed that the 3 SNPs were also associated with FeNO in non-asthmatic children (Repository Table E6).

We assessed whether there were common non-synonymous variants with deleterious functional implications in LD ($r^2 > 0.80$) with our 3 genome-wide significant SNPs using HaploReg, a data base for functional annotation of SNPs. We found 3 variants, rs11557467, rs2305480 and rs2305479 that were in high LD with rs8069176 at 17q12-q21. Rs11557467 is located in the \textit{zona pellucida binding protein 2 (ZPBP2)} gene, holding a high risk deleterious effect consisting of a missense variation resulting in a non-conservative amino acid change. Rs2305480 and rs2305479 in the GSDMB gene are both variations with a high risk of deleterious effect resulting from a missense change leading to abolishment of a protein domain. We did not find functional implications for rs3751972 and rs944722 at 17q11.2-q12. The nature of the amino-acid changes, and predicted functional significances using SIFT (http://sift.jcvi.org/), as well as the frequencies, LD with the index SNP at 17q12-q21 and \textit{P} values for FeNO association are depicted in Repository Table E7.

Subsequently, we assessed whether the identified 3 loci were eQTLs in genome-wide expression datasets of lymphoblastoid cell lines (N = 1,830)\textsuperscript{25, 26}. We found a \textit{cis} eQTL for the transcript \textit{soluble galactoside-binding lectin 9 (LGALS9)} in LD with rs944722 in two independent datasets (Repository Tables E8 and E9). \textit{LGALS9} is downstream of the \textit{NOS2} gene. Rs8069176 was associated with both GSDMB- and \textit{ORM1-like 3 (ORMDL3)} gene expression. We did not find eQTLs for rs3751972.

We tested the associations of the 3 FeNO-associated SNPs with physician-diagnosed asthma in a previously published GWA dataset (cases: n=10,365; controls: n=16,110)\textsuperscript{5}. The SNP rs8069176 was not available and we used rs2305480 as a proxy. The rs2305480[A] minor allele at the 17q12-q21 locus was associated with a decreased risk of asthma (odds ratio (OR) 0.85; 95\% CI 0.81 - 0.88; \textit{P} = 7.93×10^{-17}; Table II). This is in line with the association with lower FeNO that we found for rs8069176[A]. The SNPs rs3751972 and rs944722 were not associated with an asthma diagnosis (\textit{P} \geq 0.3). The 3 childhood FeNO-associated SNPs were not associated with adult FeNO (N = 1,211, Table II).

Finally, we explored whether common genetic variants known to be associated with physician-diagnosed asthma\textsuperscript{5} were related with childhood FeNO. We found that known asthma SNPs rs2305480 at 17q12 (\textit{GSDMB}), rs3894194 at 17q21.1 (\textit{GSDMA}), rs744910 at 15q22.33 (\textit{SMAD3}) and rs1295686 at 5q31 (\textit{IL13}) were indeed associated with childhood FeNO (all \textit{P} \leq 0.005, after Bonferroni correction; Table III). The directions of the SNP effects were as expected. The asthma SNPs together explained 0.32\% of the variance in FeNO.
DISCUSSION

We identified associations between FeNO and genetic variants at 3 loci. The common variants in and near the LYRM9 and NOS2 genes were located at 17q11.2-q12, the third signal was at 17q12-q21, harboring the ZPBP2, GSDMB, and ORMDL3 genes. The three independently associated genetic variants at the 3 loci explained 0.95% of the total variance in FeNO.

The function of the LYRM9 gene is unknown; variants in the nitric oxide synthases and arginase genes jointly contributed to differences in FeNO in previous studies\(^{28-31}\), and variation in arginase genes to asthma severity\(^{32}\). We did not find associations between the NOS2 and LYRM9 SNPs and asthma. It has been shown previously that the inducible NOS2 protein is higher in adults with severe asthma\(^{33}\). Unfortunately, we do not have data of the two SNPs and severe asthma cases. Inducible NOS2 is expressed in airway epithelium and is synthesized in response to pro-inflammatory cytokines and mediators. Expression of inducible NOS2 may be beneficial in host defense and in modulating the immune response\(^{17, 34}\). In our study genetic variants in inducible NOS2, but not in neuronal NOS1 and constitutive NOS3, were robustly associated with childhood FeNO. A previous study suggested that DNA methylation in promotor regions of arginase genes were associated with FeNO in children with asthma\(^{29}\). Thus, DNA methylation could also play an important role in epigenetic regulation of other genes for NO production.

We found a cis eQTL for the transcript LGALS9 in LD with rs944722, downstream of NOS2, and this suggests that the protein Gal-9 may be involved in the regulation of FeNO. Gal-9 plays a crucial role in immune responses, including allergic inflammation. Gal-9 was shown to inhibit allergic airway inflammation, and airway hyperresponsiveness by modulating CD44-dependent leukocyte recognition of the extracellular matrix in mice\(^{35}\). Results in guinea pigs showed that Gal-9 might be involved in prolonged eosinophil accumulation in the lung\(^{36}\). A recent study suggested a novel function of Gal-9 in mast cells and suggested that Gal-9 might be an interesting new target for the treatment of allergic disorders including asthma\(^{37}\).

The 17q12-q21 asthma locus, harboring the ZPBP2, GSDMB, and ORMDL3 ‘asthma genes’, is a complex region with high LD\(^{4, 5, 38, 39}\). GSDMB may be involved in the regulation of the growth and differentiation of epithelial cells\(^{40, 41}\). The function of the upstream ORMDL3 gene in humans is not clear. The ORMDL family genes encode for transmembrane proteins located in the endoplasmic reticulum membrane. In mice, double knockout of the ORMDL genes leads to slower growth and higher sensitivity to toxic compounds in mice\(^{42}\). The function of the downstream ZPBP2 gene is not known. Hence, the mechanisms by which 17q12-q21 variants may regulate FeNO remains to be elucidated.

The three genetic variants identified in the present study explained only a small proportion of the total variance in FeNO, while earlier work on twins indicated that most of FeNO variation is genetically determined. One explanation could be that the heritability of FeNO was overestimated. Lund \textit{et al} estimated the heritability but did not adjust for body height, a determinant of adult FeNO\(^{31}\). Furthermore, atopic adults were excluded from their
In the present study we did not exclude atopic children. Most GWA studies are underpowered to detect a large fraction of the variance conferred by polygenic traits. Big consortia showed consistent genetic architecture of > 1000 alleles for the average polygenic trait\textsuperscript{43,44}. We determined the genetic variance explained at the whole genome SNP level using a GCTA analysis\textsuperscript{27}, which was 21.3% ($P = 0.100$) in the largest cohort (Generation R Study, Caucasians only, n = 1,332). The missing heritability in our study is most likely explained by other genetic mechanisms, including missing information on causal (rare) variants, interaction between genes, between environmental factors and genes, and by epigenetic mechanisms\textsuperscript{45}. It has also been suggested that the association between asthma and FeNO may be entirely explained by atopy\textsuperscript{46}. We found an association between the 17q12-q21 childhood asthma locus and FeNO. This suggests that FeNO is related with asthma independent of allergy, as variants at the 17q12-q21 locus are not associated with specific atopic outcomes. The signals in NOS2 and LYRM9 were not associated with asthma, which conflicts with a possible causal effect of FeNO on asthma. One explanation could be that FeNO and asthma are not directly related but may have mechanisms in common. Unfortunately, we were not able to assess haplotypes or other types of genetic variation in the NOS2 and LYRM9 regions that could play a role in the development of asthma in our in silico database of patients with childhood- and adult-onset asthma.

In summary, we identified 3 independent signals that were associated with childhood FeNO in the LYRM9 and NOS2 genes, which are both located at 17q11.2-q12, and near the GSDMB gene at 17q12-q21. The 3 SNPs together explained 0.95% of the variance in FeNO. Identification of functional SNPs and haplotypes in these regions might provide novel insight in the regulation of FeNO. This study highlights that both shared and distinct genetic factors affect FeNO and childhood asthma.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Ralf JP van der Valk, PhD\#1,2,3, Liesbeth Duijts, MD PhD\#2,3,4, Nicolas J Timpson, MD PhD\#4,5, Muhammad T Salam, MD PhD, Marie Standl, MSc, John A Curtin, PhD, Jon Genuenit, MD MSc\#5, Marjan Kerhof, MD PhD, Eskil Kreiner-Møller, MD\#11,12, Alejandro Cáceres, MD PhD\#13,14,15, Anna Gref, MSc\#16, Liming Li, MD PhD, H Rob Taal, MD PhD\#1,2,3, Emmanuelle Bouzigon, MD PhD, Florence Demenais, MD\#19,20, Rachel Nadif, PhD\#21,22, Carole Ober, MD PhD, Emma E Thompson, MD PhD, Carol Estrada, PhD, Albert Hofman, MD PhD, André G Uitterlinden, PhD\#13,24, Cornéla van Duijn, PhD, Fernando Rivadeneira, MD PhD, Xia Li, MS, Sandra P Eckel, PhD, Kiros Berhane, PhD, W James Gauderman, MD PhD, Raquel Granell, PhD, David M Evans, PhD, Beate St Pourcain, PhD, Wendy McArdle, PhD, John P Kemp, MSc, George Davey Smith, MD PhD, Carla MT Tiesler, MSc, Claudia Flexeder, MSc, Angela Simpson, MD PhD, Clare S Murray, MD PhD, Oliver Fuchs, MD PhD, Dirkje S Postma, MD PhD, Klaus Bønnelykke, MD PhD, Karol Estrada, PhD, Beate St Pourcain, PhD, Wendy McArdle, PhD, John P Kemp, MSc, George Davey Smith, MD PhD, Carla MT Tiesler, MSc, Claudia Flexeder, MSc, Angela Simpson, MD PhD, Clare S Murray, MD PhD, Oliver Fuchs, MD PhD, Dirkje S Postma, MD PhD, Klaus Bønnelykke, MD PhD, Maties Torrent, MD
PhD\textsuperscript{15,29}, Martin Andersson, MD PhD\textsuperscript{30,31}, Patrick Sleiman, MD PhD\textsuperscript{32}, Hakon Hakonarson, MD PhD\textsuperscript{32}, William O Cookson, MD PhD\textsuperscript{33}, Miriam F Moffatt, PhD\textsuperscript{33}, Lavinia Paternoster, PhD\textsuperscript{4,5}, Erik Melén, MD PhD\textsuperscript{16,34}, Jordi Sunyer, MD PhD\textsuperscript{13,14,15,35}, Hans Bisgaard, MD DMSci\textsuperscript{11,12}, Gerard H Koppelman, MD PhD\textsuperscript{10,27,28}, Markus Egé, MD PhD\textsuperscript{26}, Adnan Custovic, MD PhD\textsuperscript{8}, Joachim Heinrich, PhD\textsuperscript{7}, Frank D Gilliland, MD PhD\textsuperscript{6}, Alexander J Henderson, MD\textsuperscript{4,37}, Vincent WV Jaddoe\textsuperscript{1,2,3,37}, Johan C de Jongste, MD PhD\textsuperscript{2,37}, and the EArly Genetics & Lifecourse Epidemiology (EAGLE) Consortium

Affiliations

1 The Generation R Study Group, Erasmus Medical Center, Rotterdam, The Netherlands. 2 Department of Pediatrics, Erasmus Medical Center, Rotterdam, The Netherlands. 3 Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands. 4 School of Social and Community Medicine, University of Bristol, Uk. 5 MRC Centre for Causal Analyses in Translational Epidemiology, University of Bristol, UK. 6 Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, USA. 7 Institute of Epidemiology I, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany. 8 University of Manchester, Manchester Academic Health Science Centre, University Hospital of South Manchester NHS Foundation Trust, Manchester, United Kingdom. 9 Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany. 10 University Medical Center Groningen, University of Groningen, Department of Pediatric Pulmonology and Pediatric Allergology, Beatrix Children's Hospital. 11 COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, The Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark. 12 The Danish Pediatric Asthma Center, Copenhagen University Hospital, Gentofte, Copenhagen, Denmark. 13 Center for Research in Environmental Epidemiology (CREAL), Barcelona, Catalonia, Spain. 14 Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, Catalonia, Spain. 15 Spanish consortium for Research on Epidemiology and Public Health (CIBERESP), Spain. 16 Institute of Environmental Medicine and Centre for Allergy Research, Karolinska Institutet, Stockholm, Sweden. 17 Department of Epidemiology, Harvard School of Public Health, Boston, USA. 18 Department of Biostatistics, Harvard School of Public Health, Boston, USA. 19 Inserm, UMR 946, Genetic Variation and Human Diseases Unit, F-75010, Paris, France. 20 Univ Paris Diderot, Sorbonne Paris Cité, Institut Universitaire d'Hématologie, F-75007, Paris, France. 21 Inserm, Centre for research in Epidemiology and Population Health (CEPH), U1018, Respiratory and Environmental Epidemiology Team, F-94807, Villejuif, France. 22 Univ Paris-Sud, UMRS 1018, F-94807, Villejuif, France. 23 Department of Human Genetics, University of Chicago, Chicago, IL 60637. 24 Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands. 25 Inselspital, Universitätsspital, Bern, Universitätsklinik für Kinderheilkunde, Bern, Switzerland. 26 Dr. von Hauner Children's Hospital, Ludwig Maximilian University, Munich, Germany. 27 University of Groningen, University Medical Center Groningen, Department of Pulmonology, Groningen, The Netherlands. 28 Groningen Research
Institute for Asthma and COPD (GRIAC), University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. 29 |b-salut, Area de Salut de Menorca, Balearic Islands, Spain. 30 Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden. 31 Department of Physiology, South Central Hospital, Stockholm, Sweden. 32 Center for Applied Genomics, Abramson Research Center, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. 33 National Heart and Lung Institute, Imperial College London, London SW3 6LY. 34 Sach’s Children’s Hospital, Stockholm, Sweden. 35 Pompeu Fabra University (UPF), Barcelona, Catalonia, Spain.

ACKNOWLEDGEMENTS

The acknowledgements per study can be found in the online supplement.

Funding

DE is supported by UK Medical Research Council Centre (G0600705); GS is supported by UK Medical Research Council Centre (G0600705); JK is funded by a Wellcome Trust 4-year PhD studentship in molecular, genetic, and life course epidemiology (WT083431MA); LD is supported by a European Respiratory Society/Marie Curie Joint Research Fellowship of the European Respiratory Society and the European Community’s Seventh Framework Programme FP7/2007-2013 - Marie Curie Actions under grant agreement RESPIRE, PCOFUND-GA-2008-229571 (nr MC 1226-2009); NT is supported by UK Medical Research Council Centre (G0600705); RV was partly supported by an unrestricted personal grant from GlaxoSmithKline, NL; VJ is supported by the Netherlands Organization for Health Research and Development (ZonMw 90700303, 916.10159).

Abbreviations

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATS</td>
<td>American Thoracic Society</td>
</tr>
<tr>
<td>EGEA</td>
<td>Epidemiological study on the Genetics and Environment of Asthma</td>
</tr>
<tr>
<td>eQTLs</td>
<td>expression quantitative trait loci</td>
</tr>
<tr>
<td>ERS</td>
<td>European Respiratory Society</td>
</tr>
<tr>
<td>FeNO</td>
<td>fractional concentration of nitric oxide in exhaled air</td>
</tr>
<tr>
<td>GCTA</td>
<td>genome-wide complex trait analysis</td>
</tr>
<tr>
<td>GSDMB</td>
<td>gasdermin B</td>
</tr>
<tr>
<td>GWA</td>
<td>genome-wide association</td>
</tr>
<tr>
<td>LD</td>
<td>linkage disequilibrium</td>
</tr>
<tr>
<td>LGALS9</td>
<td>soluble galactoside-binding lectin 9</td>
</tr>
<tr>
<td>LYRM9</td>
<td>LYR motif containing 9</td>
</tr>
<tr>
<td>NOS</td>
<td>nitric oxide synthases</td>
</tr>
<tr>
<td>ORMDL3</td>
<td>ORM1-like 3</td>
</tr>
<tr>
<td>SNPs</td>
<td>single nucleotide polymorphisms</td>
</tr>
<tr>
<td>ZPBP2</td>
<td>zona pellucida binding protein 2</td>
</tr>
</tbody>
</table>
REFERENCES


Key messages

- We identified 3 independent genetic variants associated with childhood FeNO, one of the variants was also associated with physician-diagnosed asthma.
- Future studies are needed to unravel the mechanisms by which the variants regulate childhood FeNO and asthma.
Capsule summary

This study highlights that both shared and distinct genetic factors affect childhood FeNO and asthma.
Stage 1: genome-wide association analyses of FeNO in children
N = 8,858
- ALSPAC1 (n = 949)
- ALSPAC2 (n = 794)
- BAMSE (n = 97)
- CHS1 (n = 708)
- CHS2 (n = 1,155)
- COPSAC (n = 313)
- GABRIELA (n = 358)
- GENERATIONR (n = 2,572)
- INMA (n = 153)
- ISA1 (n = 255)
- GINI/ISA2 (n = 585)
- MAA5 (n = 600)
- PIAMA1 (n = 149)
- PIAMA2 (n = 170)

Stage 2: follow-up of 3 lead SNPs
- Analysis of lead SNPs conditioned on current asthma (n = 7,786)
- Analysis of lead SNPs in non-asthmatic children (n = 6,711)
- Functional variants in LD with lead SNPs (HaploReg and SIFT search)
- eQTLs in LCLs in LD with lead SNPs (discovery n = 955, replication n = 875)
- Lead SNPs and physician-diagnosed asthma (cases: n=10,365; controls: n=15,110)
- Lead SNPs and adult FeNO (EGEA, n = 610, Hutterites, n = 601)

Stage 3: cross-phenotyping
- Associations of known physician-diagnosed asthma loci and FeNO (N = 8,858)

Figure I. Study design
SNPs, single nucleotide polymorphisms; LD, linkage disequilibrium; eQTLs, expression quantitative trait loci; LCLs, lymphoblastoid cell lines.
Figure II. QQ and Manhattan plots of 2,253,077 SNPs of 14 GWA studies (N = 8,858)

QQ plot of 2,253,077 SNPs of 14 GWA studies. The black dots represent observed $P$ values and the red line represents the expected $P$ values under the null distribution. Manhattan plot showing the association $P$ values of FeNO of the 14 studies. The $-\log_{10}$ of the $P$ value for each of 2,253,077 SNPs (y-axis) is plotted against the genomic position (x-axis).
Figure III. Association plots of the 17q11.2-q12 and 17q12-q21 regions
For both the 17q11.2-q12 and 17q12-q21 regions, SNPs are plotted with their $P$ values (as $-\log_{10}$ values; left y-axis) as a function of genomic position (x-axis). Estimated recombination rates (right y-axis) taken from HapMap are plotted to reflect the local LD structure around the top associated SNP (purple circle) and their correlated proxies (according to a blue to red scale from $r^2 = 0$ to 1). Triangles represent nonsynonymous SNPs.
Figure IV. Forest plots of the associations between FeNO and the 3 SNPs associated with FeNO at $P < 5 \times 10^{-8}$

Forest plots of the associations between FeNO and the SNPs in LYRM9 (a), NOS2 (b) and near ZPB2-GSDMB (c) at $P < 5 \times 10^{-8}$. In each plot, the triangle indicates the effect size and the confidence interval in the 14 studies. The $P$ values in the plots are without genomic control correction.
Table I

Summary statistics of the 3 SNPs at $P < 5 \times 10^{-8}$.

<table>
<thead>
<tr>
<th>Marker</th>
<th>MAF</th>
<th>$\beta$</th>
<th>S.E.</th>
<th>$P$</th>
<th>$I^2$</th>
<th>HetP</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs3751972[C] at 17q11.2</td>
<td>0.25</td>
<td>0.086</td>
<td>0.014</td>
<td>1.97×10^{-10}</td>
<td>27.4</td>
<td>0.161</td>
</tr>
<tr>
<td>rs944722[C] at 17q11.2-q12</td>
<td>0.38</td>
<td>−0.073</td>
<td>0.012</td>
<td>1.28×10^{-09}</td>
<td>37.8</td>
<td>0.075</td>
</tr>
<tr>
<td>rs8069176[A] at 17q12-q21</td>
<td>0.43</td>
<td>−0.066</td>
<td>0.012</td>
<td>1.88×10^{-08}</td>
<td>0.0</td>
<td>0.668</td>
</tr>
</tbody>
</table>

Single nucleotide polymorphisms (SNPs) markers are identified according to their standard rs numbers (NCBI build 36). Independent SNPs with a genome-wide significant effect on FeNO levels in children are shown ($P < 5 \times 10^{-8}$). The total sample includes data of 14 independent GWA datasets (N = 8,858). MAF, minor allele frequency; S.E., standard error. $\beta$ reflects differences in natural log-transformed FeNO per minor allele. $P$ values are obtained from linear regression of each SNP against natural log-transformed FeNO adjusted for sex and age at time of measurement (fixed-effect additive genetic model). Derived inconsistency statistic $I^2$ and HetP values reflect heterogeneity across studies with the use of Cochran’s Q tests.
### Table II

<table>
<thead>
<tr>
<th>Marker</th>
<th>OR (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proxy for rs3751972: rs4796222[A] (r²=1.000; D²=1.000) at 17q11.2 (LYRM9)</td>
<td>0.98 (0.93-1.02)</td>
<td>0.303</td>
</tr>
<tr>
<td>Proxy for rs944722: rs2274894[T] (r²=0.967; D²=1.000) at 17q11.2-q12 (NOS2)</td>
<td>1.00 (0.96-1.04)</td>
<td>0.983</td>
</tr>
<tr>
<td>Proxy for rs8069176: rs2305480[A] (r²=1.000; D²=1.000) at 17q12-q21 (nearest genes ZPBP2-GSDMB)</td>
<td>0.85 (0.81-0.88)</td>
<td>7.93×10⁻¹⁷</td>
</tr>
</tbody>
</table>

**Physician-diagnosed asthma (cases = 10,365 : controls = 16,110)**

**Adult FeNO**

<table>
<thead>
<tr>
<th>Marker (EGEA, n = 610)</th>
<th>β</th>
<th>S.E.</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs3751972[C] at 17q11.2 (LYRM9)</td>
<td>0.125</td>
<td>0.065</td>
<td>0.057</td>
</tr>
<tr>
<td>rs944722[C] at 17q11.2-q12 (NOS2)</td>
<td>−0.015</td>
<td>0.061</td>
<td>0.802</td>
</tr>
<tr>
<td>rs8069176[A] at 17q12-q21 (nearest genes ZPBP2-GSDMB)</td>
<td>−0.113</td>
<td>0.062</td>
<td>0.067</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Marker (Hutterites, n = 601)</th>
<th>Z score</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proxy for rs3751972: rs4796228[G] (r²=0.659; D²=1.000) at 17q11.2 (LYRM9)</td>
<td>−1.536</td>
<td>0.125</td>
</tr>
<tr>
<td>Proxy for rs944722: rs2314809[T] (r²=0.967; D²=1.000) at 17q11.2-q12 (NOS2)</td>
<td>−2.322</td>
<td>0.020</td>
</tr>
<tr>
<td>Proxy for rs8069176: rs11078927[T] (r²=1.000; D²=1.000) at 17q12-q21 (nearest genes ZPBP2-GSDMB)</td>
<td>0.505</td>
<td>0.613</td>
</tr>
</tbody>
</table>

Single nucleotide polymorphisms (SNPs) markers are identified according to their standard rs numbers (NCBI build 36). Independent SNPs with a genome-wide significant effect on FeNO levels in children are shown (P < 5x10⁻⁸) in relation to physician-diagnosed asthma⁵ and adult FeNO. S.E., standard error. Odds ratios (OR) with 95% confidence interval (CI) for physician-diagnosed asthma⁵. β reflects differences in natural log-transformed FeNO per minor allele for adult FeNO in EGEA. Z-score reflects the strength of the association between SNP and natural log-transformed FeNO and the direction of the effect of the minor allele in Hutterites.
Table III

Association of known physician-diagnosed asthma loci, from a previous GWA study⁵ with childhood FeNO.

<table>
<thead>
<tr>
<th>Marker</th>
<th>MAF</th>
<th>β</th>
<th>S.E.</th>
<th>P</th>
<th>I²</th>
<th>HetP</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs2305480[A] decreasing risk-allele at 17q12 (GSDMB)</td>
<td>0.42</td>
<td>−0.065</td>
<td>0.012</td>
<td>2.83×10⁻⁸⁸</td>
<td>0.0</td>
<td>0.731</td>
</tr>
<tr>
<td>rs3894194[A] increasing risk-allele at 17q21.1 (GSDMA)</td>
<td>0.47</td>
<td>0.048</td>
<td>0.012</td>
<td>6.35×10⁻⁵⁵</td>
<td>9.5</td>
<td>0.349</td>
</tr>
<tr>
<td>rs744910[A] decreasing risk-allele at 15q22.33 (SMAD3)</td>
<td>0.49</td>
<td>−0.039</td>
<td>0.012</td>
<td>8.41×10⁻⁶⁴</td>
<td>0.0</td>
<td>0.491</td>
</tr>
<tr>
<td>rs1295680[T] increasing risk-allele at 5q31 (IL13)</td>
<td>0.27</td>
<td>0.044</td>
<td>0.014</td>
<td>1.25×10⁻⁶³</td>
<td>4.6</td>
<td>0.401</td>
</tr>
<tr>
<td>rs1342326[C] increasing risk-allele at 9p24.1 (IL33)</td>
<td>0.17</td>
<td>0.025</td>
<td>0.016</td>
<td>0.119</td>
<td>0.0</td>
<td>0.515</td>
</tr>
<tr>
<td>rs9273349[T] decreasing risk-allele at 6p21.3 (HLA-DQ)</td>
<td>0.37</td>
<td>−0.022</td>
<td>0.022</td>
<td>0.310</td>
<td>0.0</td>
<td>0.802</td>
</tr>
<tr>
<td>rs11071559[T] decreasing risk-allele at 15q22.2 (RORA)</td>
<td>0.14</td>
<td>−0.014</td>
<td>0.017</td>
<td>0.415</td>
<td>0.0</td>
<td>0.651</td>
</tr>
<tr>
<td>rs3771160[A] decreasing risk-allele at 2q12 (IL18R1)</td>
<td>0.35</td>
<td>−0.009</td>
<td>0.012</td>
<td>0.463</td>
<td>7.4</td>
<td>0.371</td>
</tr>
<tr>
<td>rs2284033[A] decreasing risk-allele at 22q13.1 (IL2RB)</td>
<td>0.42</td>
<td>0.005</td>
<td>0.012</td>
<td>0.705</td>
<td>0.0</td>
<td>0.633</td>
</tr>
<tr>
<td>rs2073643[T] increasing risk-allele at 5q23.3 (SLC22A5)</td>
<td>0.47</td>
<td>0.000</td>
<td>0.012</td>
<td>0.993</td>
<td>0.0</td>
<td>0.590</td>
</tr>
</tbody>
</table>

Single nucleotide polymorphisms (SNPs) markers are identified according to their standard rs numbers (NCBI build 36). We explored whether common genetic variants known to be related with physician-diagnosed asthma⁵ were associated with childhood FeNO. The total sample includes data of 14 independent GWA datasets (N = 8,858). MAF, minor allele frequency; S.E., standard error. β reflects differences in natural log-transformed FeNO per minor allele. P values are obtained from linear regression of each SNP against natural log-transformed FeNO adjusted for sex and age at time of measurement (fixed-effect additive genetic model). Derived inconsistency statistic I² and HetP values reflect heterogeneity across studies with the use of Cochran’s Q tests.